Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) have earned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.57.
CBAY has been the topic of several recent research reports. BTIG Research initiated coverage on CymaBay Therapeutics in a report on Thursday, March 9th. They set a “buy” rating and a $15.00 price objective on the stock. StockNews.com lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 15th. SVB Leerink raised their target price on CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 8th. Piper Sandler raised their target price on CymaBay Therapeutics from $12.00 to $19.00 and gave the stock an “overweight” rating in a research report on Sunday, January 29th. Finally, Oppenheimer raised their target price on CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 7th.
Insider Buying and Selling at CymaBay Therapeutics
In other CymaBay Therapeutics news, General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $10.37, for a total transaction of $51,850.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $10.37, for a total value of $51,850.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dennis D. Kim sold 7,781 shares of the stock in a transaction on Thursday, April 13th. The stock was sold at an average price of $8.98, for a total value of $69,873.38. Following the completion of the sale, the insider now owns 20,000 shares in the company, valued at approximately $179,600. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,849 shares of company stock valued at $1,390,672. Company insiders own 5.60% of the company’s stock.
Institutional Inflows and Outflows
CymaBay Therapeutics Price Performance
Shares of NASDAQ:CBAY opened at $9.11 on Monday. The company has a market capitalization of $888.32 million, a P/E ratio of -7.72 and a beta of 0.27. CymaBay Therapeutics has a 1 year low of $1.81 and a 1 year high of $11.22. The business’s 50 day simple moving average is $9.51 and its 200 day simple moving average is $7.24.
CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) last issued its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.30). During the same period last year, the company posted ($0.34) EPS. On average, sell-side analysts anticipate that CymaBay Therapeutics will post -1.01 EPS for the current fiscal year.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
- Get a free copy of the StockNews.com research report on CymaBay Therapeutics (CBAY)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.